Nebulized hypertonic saline may significantly reduce hospital admissions and shorten recovery times for infants with acute bronchiolitis, according to a meta-analysis of 35 randomized trials published on October 29, 2026, in ERJ Open Research.
The findings suggest this therapy outperforms standard normal saline in early-stage symptom management.
Bronchiolitis, a common respiratory tract infection in infants, often results in significant hospital volume during peak seasons. As reported by Medscape on November 13, 2026, the systematic review analyzed 4,723 infants aged 24 months or younger, comparing the efficacy of hypertonic saline—a solution with a higher salt concentration than blood—against the standard 0.9% normal saline.
The data indicate a 26% reduction in the relative risk of hospital admission for those treated with the hypertonic intervention.
- Hypertonic saline works by drawing water into the airways, helping to thin mucus and clear obstructions more effectively than regular saline.
- The treatment is typically administered via a nebulizer—a device that turns liquid medicine into a fine mist for the infant to breathe in.
The research team, led by Stephanie Thee of Charité – Universitätsmedizin Berlin, found that infants receiving hypertonic saline concentrations between 3% and 7% experienced improved clinical symptom scores at 24 and 48 hours. Across 10 specific trials, the pooled relative risk for hospital admission stood at 0.74, with a 95% confidence interval of 0.60 to 0.90. This statistical significance highlights a measurable clinical advantage for early intervention in emergency or urgent care settings.
However, the study authors noted substantial heterogeneity—or statistical variation—across the 35 trials included in the analysis (I² = 88.9% and 91.7% for symptom scores).
This variability, potentially stemming from differences in study design, regional clinical practices, or the specific concentration of saline used, suggests that the results may not be universally applicable across all healthcare environments. Data regarding symptom severity at the 72-hour mark did not reach statistical significance, and the long-term duration of the benefit is unknown.
| Outcome Metric | Result (Relative Risk/Mean Difference) | 95% Confidence Interval |
|---|---|---|
| Hospital Admission Risk | 0.74 (Relative Risk) | 0.60 – 0.90 |
| Symptom Score (24h) | 0.48 (Std. Mean Diff.) | 0.27 – 0.70 |
| Symptom Score (48h) | 0.53 (Std. Mean Diff.) | 0.14 – 0.92 |
| Hospital Stay Duration | -0.44 days | -0.68 to -0.21 |
Transparency regarding the research origins is essential for clinicians evaluating these results. The study received funding from PARI GmbH, a manufacturer of nebulization technology, and several authors reported financial ties to the company, including employment and consulting fees. Such disclosures are standard in peer-reviewed literature to allow the medical community to weigh potential conflicts of interest against the clinical data provided.
The analysis was also limited by the scope of existing literature, which focused primarily on trials conducted in Asia. Because the study design only compared hypertonic saline to normal saline, it remains unclear whether the intervention is superior to no inhaled therapy or minimal handling protocols.
As the authors wrote, “[The] available randomized evidence supports HS [hypertonic saline] as an adjunct to supportive care that performs better than NS [normal saline] in infants with bronchiolitis, particularly for early symptom improvement and length of stay.”
- ERJ Open Research: Systematic review and meta-analysis of nebulized hypertonic saline trials (2026).
- Medscape: Clinical reporting on the impact of hypertonic saline in pediatric respiratory care (November 13, 2026).
